CG Oncology Stakes Its Future on Best-in-Class Bladder Cancer Therapy, Poised for Massive Upside Pending Regulatory Success
Overview
CG Oncology Inc. is a late-stage clinical biopharmaceutical company focused on developing cretostimogene grenadenorepvec, a novel oncolytic immunotherapy for high-risk, BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC). The company's future hinges entirely on the success of this single asset, backed by strong Phase 3 trial results that show high and durable complete response rates with excellent safety. A robust cash position extends the company’s runway past key regulatory milestones, with the pivotal BLA submission expected in Q4 2025. Despite market uncertainties and the inherent risks of binary outcomes in drug approval, the risk/reward profile appears attractive if upcoming milestones are met, given the apparent disconnect between CG Oncology’s current valuation and the probability-adjusted future cash flows from cretostimogene.